Physician profile
Hyewon An
NPI 1407243843
$2,778.62
in general payments reported to CMS, 2019-2025
21 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $788 · 2022: $690 · 2023: $646 · 2024: $413 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,240.49 | 2021-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $639.89 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $221.19 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.56 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals Lp | $130.23 | 2022-2025 | Farxiga |
| Lilly USA, LLC | $103.45 | 2021-2025 | Mounjaro |
| Esperion Therapeutics, INC. | $41.78 | 2021-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $30.94 | 2021-2022 | |
| Astellas Pharma US INC | $29.33 | 2021-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $28.53 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $25.44 | 2021 | |
| Exact Sciences Corporation | $19.75 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $16.89 | 2025 | |
| Eisai INC. | $15.47 | 2024 | |
| Philips North America LLC | $14.96 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $14.71 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.39 | 2022 | |
| Ibsa Pharma INC. | $14.22 | 2025 | Tirosint, Flector, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.86 | 2023 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $12.40 | 2022 | |
| Abbvie INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hyewon An listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.